Steroidogenesis vs. steroid uptake in the heart: Do corticosteroids mediate effects via cardiac mineralocorticoid receptors?

Journal of Hypertension

Volumn 28, Issue 5, 2010, Pages 1044-1053

  Chai, Wenxia ^a   Hofland, Johannes ^b   Jansen, Pieter M ^a   Garrelds, Ingrid M ^a   De Vries, René ^a   Van Den Bogaerdt, Antoon J ^a   Feelders, Richard A ^b   De Jong, Frank H ^b   Danser, Ah Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Medicine   (United States)

Author keywords

Aldosterone; Cortisol; Mineralocorticoid receptor; Nongenomic effect

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; CANRENOIC ACID; CARBENOXOLONE; CORTICOSTERONE; ENZYME; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MESSENGER RNA; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; STEROID; STEROID SYNTHESIZING ENZYME; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CHILD; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; FEMALE; GENE EXPRESSION; HALF LIFE TIME; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HORMONE ACTION; HORMONE SYNTHESIS; HORMONE TRANSPORT; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; INOTROPISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; STEADY STATE; STEROIDOGENESIS;

EID: 77951267891     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328335c381     Document Type: Article

References (38)

1. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JMJ, Danser AHJ. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol 2005; 145:664-671. (Pubitemid 41032638)
2. Chai W, Garrelds IM, de Vries R,Batenburg WW, van Kats JP, Danser AHJ. Nongenomic effects of aldosterone in the human heart. Interaction with angiotensin II. Hypertension 2005; 46:701-706. (Pubitemid 43186741)
3. Chai W, Garrelds IM, de Vries R, Danser AHJ. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension 2006; 47:665-670. (Pubitemid 43740236)
4. Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 2002; 40:130-135. (Pubitemid 34840087)
5. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension 2004; 44:751-757. (Pubitemid 39435249)
6. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003; 108:2400-2406. (Pubitemid 37413549)
7. Schmidt BMW, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003; 42:156-160. (Pubitemid 36944589)
8. 2\+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005; 146:973-980. (Pubitemid 40289282)
9. Mihailidou AS, Mardini M, Funder JW. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 2004; 145:773-780. (Pubitemid 38183820)
10. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47:656-664. (Pubitemid 43740235)
11. Alzamora R, Michea L, Marusic ET. Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 2000; 35:1099-1104. (Pubitemid 30327264)
12. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237:268-275. (Pubitemid 17095145)
13. Lombès M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1994; 135:834-840. (Pubitemid 24271168)
14. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005; 93:121-125.
15. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology 2004; 145:4796-4802. (Pubitemid 39551092)
16. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96:643-650.
17. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111:3087-3094. (Pubitemid 40847786)
18. Schwinger RHG, Müller-Ehmsen J, Frank K, Koch A, Erdmann E. Enhanced sensitivity of the failing human myocardium to cardiac glycosides and Na(\+)-channel activators. Am Heart J 1996; 131:988-993. (Pubitemid 26135765)
19. Hofland J, Timmerman MA,deHerder WW, van Schaik RHN, de Krijger RR, de Jong FH. Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms. Clin Endocrinol (Oxf) 2006; 65:792-799. (Pubitemid 44772360)
20. MaassenVanDenBrink A, de Vries R, Saxena PR, Schalekamp MADH, Danser AHJ. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res 1999; 44:407-415. (Pubitemid 29474102)
21. van Esch JHM, Oosterveer CR, Batenburg WW, van Veghel R, Danser AHJ. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor? Eur J Pharmacol 2008; 588:286-293.
22. van Esch JHM, Schuijt MP, Sayed J, Choudry Y, Walther T, Danser AHJ. AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation. Br J Pharmacol 2006; 148:452-458. (Pubitemid 43882081)
23. Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S. Effects of canrenone on aorta and right ventricle of the rat. J Cardiovasc Pharmacol 2001; 37:540-547. (Pubitemid 32377910)
24. Caballero R, Moreno I, Gonzalez T, Arias C, Valenzuela C, Delpon E, et al. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 2003; 107:889-895. (Pubitemid 36241049)
25. Sainte-Marie Y, Nguyen Dinh Cat A, Perrier R, Mangin L, Soukaseum C, Peuchmaur M, et al. Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB J 2007; 21:3133-3141. (Pubitemid 47565533)
26. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111:3025-3033. (Pubitemid 40847778)
27. Mihailidou AS, Loan Le TY, Mardini M,Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54:1306-1312.
28. Kayes-WandoverKM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000; 85:2519-2525. (Pubitemid 32269210)
29. Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001; 86:5121-5126. (Pubitemid 33070224)
30. Guryev O, Carvalho RA, Usanov S, Gilep A, Estabrook RW. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc Natl Acad Sci USA 2003; 100:14754-14759. (Pubitemid 37517963)
31. Schuijt MP, van Kats JP, de Zeeuw S, Duncker DJ, Verdouw PD, Schalekamp MADH, et al. Cardiac interstitial fluid levels of angiotensin I and II in the pig. J Hypertens 1999; 17:1885-1891. (Pubitemid 30345327)
32. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997; 29:1240-1251.
33. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, et al. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in postinfarct rat hearts. Hypertens Res 2007; 30:427-437. (Pubitemid 46958893)
34. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93:69-76. (Pubitemid 36859043)
35. Milik E, Szczepanska-Sadowska E, Maslinski W, Cudnoch-Jedrzejewska A. Enhanced expression of mineralocorticoid receptors in the heart after the myocardial infarct in rats. J Physiol Pharmacol 2007; 58:745-755.
36. Yoshida M, Ma J, Tomita T, Morikawa N, Tanaka N, Masamura K, et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005; 11:12-16.
37. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321. (Pubitemid 36384098)
38. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.